ATE279430T1 - Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen - Google Patents

Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen

Info

Publication number
ATE279430T1
ATE279430T1 AT99912297T AT99912297T ATE279430T1 AT E279430 T1 ATE279430 T1 AT E279430T1 AT 99912297 T AT99912297 T AT 99912297T AT 99912297 T AT99912297 T AT 99912297T AT E279430 T1 ATE279430 T1 AT E279430T1
Authority
AT
Austria
Prior art keywords
life
biologically active
serum half
improving
upa
Prior art date
Application number
AT99912297T
Other languages
English (en)
Inventor
Robert J Drummond
Steve Rosenberg
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE279430T1 publication Critical patent/ATE279430T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
AT99912297T 1998-03-05 1999-03-05 Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen ATE279430T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7696498P 1998-03-05 1998-03-05
PCT/US1999/004899 WO1999045026A1 (en) 1998-03-05 1999-03-05 Method for increasing the serum half-life of a biologically active molecule

Publications (1)

Publication Number Publication Date
ATE279430T1 true ATE279430T1 (de) 2004-10-15

Family

ID=22135286

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99912297T ATE279430T1 (de) 1998-03-05 1999-03-05 Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen

Country Status (6)

Country Link
US (4) US6423685B1 (de)
EP (1) EP1062230B1 (de)
JP (1) JP2002505338A (de)
AT (1) ATE279430T1 (de)
DE (1) DE69921102T2 (de)
WO (1) WO1999045026A1 (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999045026A1 (en) * 1998-03-05 1999-09-10 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule
US6887674B1 (en) * 1998-04-13 2005-05-03 California Institute Of Technology Artery- and vein-specific proteins and uses therefor
DE69934425T2 (de) 1998-10-23 2007-09-27 Amgen Inc., Thousand Oaks Thrombopoietin substitute
JP2004524810A (ja) * 2000-09-18 2004-08-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｃｒｉｐｔｏ変異体およびその使用
UY26929A1 (es) * 2000-09-29 2002-04-26 Abbott Lab Polipéptidos antiangiogénicos y métodos para inhibir la angiogénesis
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
EP1837031B1 (de) * 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Methoden und Kompositionen um Diabetes zu behandeln
AT413031B (de) * 2002-08-06 2005-10-15 Stockinger Hannes Dr Verwendung von cd222 oder eines abgeleiteten peptids zur hemmung von fibrinolyse, zelladhäsion und zellmigration in vitro
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US20040229810A1 (en) * 2002-10-22 2004-11-18 Antonio Cruz Gastrin compositions and formulations, and methods of use and preparation
MXPA05006945A (es) * 2002-12-26 2005-12-14 Mountain View Pharmaceuticals Conjugados polimericos de citoquinas, quimiocinas, factores de crecimiento, hormonas polipeptidicas y sus antagonistas con actividad conservada de union al receptor.
MXPA05006944A (es) * 2002-12-26 2005-12-14 Mountain View Pharmaceuticals Conjugados polimericos de interferon-beta cion potencia biologica aumentada.
US7553930B2 (en) 2003-01-06 2009-06-30 Xencor, Inc. BAFF variants and methods thereof
JP4339797B2 (ja) * 2003-01-18 2009-10-07 ペスフェア カンパニー リミテッド 非標的部位のアミンが保護されたペプチド、その製造方法、及びこれを利用したｐｅｇが特異的に接合されたペプチドの製造方法
US7381410B2 (en) * 2003-03-12 2008-06-03 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
CA2518898A1 (en) * 2003-03-12 2004-09-23 Vasgene Therapeutics, Inc. Nucleic acid compounds for inhibiting angiogenesis and tumor growth
EP1613274B1 (de) * 2003-04-15 2010-03-03 GlaxoSmithKline LLC Humane il-18 substitutionsmutanten und deren konjugate
US7261882B2 (en) 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
US20050131028A1 (en) * 2003-09-11 2005-06-16 Pharmacia Corporation Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
US20060228331A1 (en) * 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
EP2633866A3 (de) * 2003-10-17 2013-12-18 Novo Nordisk A/S Kombinationstherapie
EP1718664A4 (de) 2004-02-02 2008-08-13 Ambrx Inc Modifizierte menschliche vierhelix-bündel-peptide und ihre verwendungen
US7977463B2 (en) * 2004-03-12 2011-07-12 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth
ATE492564T1 (de) 2004-03-12 2011-01-15 Vasgene Therapeutics Inc Ephb4-bindende antikörper zur inhibierung von angiogenese und tumorwachstum
KR101699142B1 (ko) * 2004-06-18 2017-01-23 암브룩스, 인코포레이티드 신규 항원-결합 폴리펩티드 및 이의 용도
JP2008505928A (ja) * 2004-07-08 2008-02-28 アムジェン　インコーポレーテッド 治療用ペプチド
BRPI0512396A (pt) * 2004-07-21 2008-03-11 Ambrx Inc polipeptìdeos biossintéticos utilizando aminoácidos codificados não naturalmente
EP2301963A1 (de) * 2004-09-23 2011-03-30 Vasgene Therapeutics, Inc. Polypeptidverbindungen zur Hemmung von Angiogenese und Tumorwachstum
EP1805216A2 (de) * 2004-10-18 2007-07-11 Novo Nordisk A/S Wachstumshormonkonjugate
ATE541934T1 (de) 2004-12-22 2012-02-15 Ambrx Inc Zusammensetzungen von aminoacyl-trna-synthetase und verwendungen davon
US8080391B2 (en) 2004-12-22 2011-12-20 Ambrx, Inc. Process of producing non-naturally encoded amino acid containing high conjugated to a water soluble polymer
BRPI0519170A8 (pt) 2004-12-22 2018-05-08 Ambrx Inc formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado
US7939496B2 (en) 2004-12-22 2011-05-10 Ambrx, Inc. Modified human growth horomone polypeptides and their uses
CA2927595C (en) 2004-12-22 2023-01-31 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
ES2357550T3 (es) 2005-04-18 2011-04-27 Novo Nordisk A/S Variantes de la il-21.
WO2006125201A2 (en) * 2005-05-19 2006-11-23 Centocor, Inc. Anti-biotin-pegylated-mcp-1 mutein antibodies, compositions, methods and uses
CN101247821B (zh) 2005-06-03 2013-01-23 Ambrx公司 经改良人类干扰素分子和其用途
EP1937291A2 (de) * 2005-09-23 2008-07-02 Vasgene Therapeutics, Inc. Verwendung von mitteln gegen ephrin2 zur behandlung oder prävention von virusinfektionen
CN106443006A (zh) 2005-11-16 2017-02-22 Ambrx公司 包括非天然氨基酸的方法和组合物
JO3324B1 (ar) 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
DK2064333T3 (da) 2006-09-08 2014-05-05 Ambrx Inc Suppressor-trna-transkription i hvirveldyrceller
CN106190983B (zh) 2006-09-08 2019-05-28 Ambrx公司 用于脊椎动物细胞的杂合抑制tRNA
MX2009002523A (es) 2006-09-08 2009-03-20 Ambrx Inc Polipeptido de plasma humano modificado o andamios fc y sus usos.
AU2007310777A1 (en) 2006-10-26 2008-05-02 Novo Nordisk A/S IL-21 variants
CA2671665A1 (en) * 2006-12-21 2008-06-26 Novo-Nordisk A/S Interleukin-21 variants with altered binding to the il-21 receptor
KR20140012199A (ko) 2007-03-30 2014-01-29 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
JP2010525821A (ja) 2007-05-02 2010-07-29 アンブルックス，インコーポレイテッド 修飾ＩＦＮβポリペプチドおよびこれらの使用
EP3127549B1 (de) 2007-06-22 2019-12-18 Children's Medical Center Corporation Verfahren und verwendung von einem fragment von saposin a
KR101656107B1 (ko) 2007-11-20 2016-09-08 암브룩스, 인코포레이티드 변형된 인슐린 폴리펩티드 및 이의 용도
NZ602170A (en) 2008-02-08 2014-03-28 Ambrx Inc Modified leptin polypeptides and their uses
CA2729851C (en) 2008-07-23 2019-01-15 Ambrx, Inc. Modified bovine g-csf polypeptides and their uses
US9121024B2 (en) 2008-09-26 2015-09-01 Ambrx, Inc. Non-natural amino acid replication-dependent microorganisms and vaccines
CN107022020A (zh) 2008-09-26 2017-08-08 Ambrx公司 修饰的动物促红细胞生成素多肽和其用途
US8293100B2 (en) 2009-03-13 2012-10-23 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography
US20120071401A1 (en) 2009-04-10 2012-03-22 Amylin Pharamaceuticals, Inc. Amylin agonist compounds for estrogen-deficient mammals
JP5751641B2 (ja) 2009-05-06 2015-07-22 ヤンセン バイオテツク，インコーポレーテツド メラノコルチン受容体結合コンジュゲート
RU2012126101A (ru) 2009-11-23 2013-12-27 АМИЛИН ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи,США Полипептидный конъюгат
EP3925670A1 (de) 2009-12-17 2021-12-22 Children's Medical Center, Corp. Aus saposin-a gewonnene peptide und verwendungen davon
CN107674121A (zh) 2009-12-21 2018-02-09 Ambrx 公司 经过修饰的牛促生长素多肽和其用途
CN104017063A (zh) 2009-12-21 2014-09-03 Ambrx公司 经过修饰的猪促生长素多肽和其用途
EP2528938A4 (de) 2010-01-27 2013-10-23 Childrens Medical Center Proangiogene fragmente von prominin-1 und verwendungen davon
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
EP3572091B1 (de) 2010-08-17 2023-12-13 Ambrx, Inc. Modifizierte relaxinpolypeptide und deren verwendungen
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
CA2837167A1 (en) 2011-05-27 2012-12-06 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives
CN103717595A (zh) 2011-05-27 2014-04-09 Ambrx公司 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途
CA2860226C (en) 2011-12-22 2022-10-18 Randolph S. Watnick Saposin-a derived peptides and uses thereof
WO2013103896A1 (en) 2012-01-06 2013-07-11 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
MX363116B (es) 2012-06-07 2019-03-11 Ambrx Inc Conjugados anticuerpo-farmaco de antigeno de membrana especifico de prostata.
BR112014030278A2 (pt) 2012-06-08 2017-06-27 Sutro Biopharma Inc anticorpo, e, composição.
KR20150023729A (ko) 2012-06-14 2015-03-05 암브룩스, 인코포레이티드 핵 수용체 리간드 폴리펩티드에 접합된 항-psma 항체
EP3488870B1 (de) 2012-06-19 2024-03-20 Ambrx, Inc. Anti-cd70-antikörper-arzneimittelkonjugate
EP3135690A1 (de) 2012-06-26 2017-03-01 Sutro Biopharma, Inc. Modifizierte fc-proteine mit stellenspezifischen nichtnatürlichen aminosäureresten, konjugate daraus, verfahren zu deren herstellung und verfahren zu deren verwendung
EP2971166B1 (de) 2013-03-14 2021-05-19 Children's Medical Center Corporation Psap peptide zur behandlung von cd36-exprimierenden krebs
US9764039B2 (en) 2013-07-10 2017-09-19 Sutro Biopharma, Inc. Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
CN106659764B (zh) 2014-03-26 2021-11-02 儿童医学中心公司 环状鞘脂激活蛋白原肽及其用途
TWI705071B (zh) 2014-10-24 2020-09-21 美商必治妥美雅史谷比公司 經修飾之fgf-21多肽及其用途
CN109069664B (zh) 2016-01-27 2022-05-13 苏特罗生物制药公司 抗cd74抗体偶联物，包含抗cd74抗体偶联物的组合物以及抗cd74抗体偶联物的使用方法
SG10201912034UA (en) 2017-02-08 2020-02-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
US20200207859A1 (en) 2017-07-26 2020-07-02 Sutro Biopharma, Inc. Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
WO2019055909A1 (en) 2017-09-18 2019-03-21 Sutro Biopharma, Inc. ALPHA ANTI-FOLATE ANTIBODY-RECEPTOR CONJUGATES AND USES THEREOF
CN116948006A (zh) 2018-09-11 2023-10-27 北京泰德制药股份有限公司 白介素-2多肽偶联物及其用途
US20220047716A1 (en) 2018-09-17 2022-02-17 Sutro Biopharma, Inc. Combination therapies with anti-folate receptor antibody conjugates
AU2019361206A1 (en) 2018-10-19 2021-06-03 Ambrx, Inc. Interleukin-10 polypeptide conjugates, dimers thereof, and their uses
CN109400695B (zh) * 2018-10-31 2020-06-30 中南大学湘雅医院 一种多肽的修饰方法及应用
US11613744B2 (en) 2018-12-28 2023-03-28 Vertex Pharmaceuticals Incorporated Modified urokinase-type plasminogen activator polypeptides and methods of use
PE20211664A1 (es) 2018-12-28 2021-08-26 Catalyst Biosciences Inc Polipeptidos de activador de plasminogeno, tipo urocinasa, modificados y metodos de uso
KR20210136014A (ko) 2019-02-12 2021-11-16 암브룩스, 인코포레이티드 항체-tlr 작용제 콘쥬게이트를 함유하는 조성물, 방법 및 이의 용도
EP3962951A1 (de) 2019-05-03 2022-03-09 Sutro Biopharma, Inc. Anti-bcma-antikörper-konjugate
EP3980423A1 (de) 2019-06-10 2022-04-13 Sutro Biopharma, Inc. 5h-pyrrolo[3,2-d]pyrimidin-2,4-diaminverbindungen und ihre antikörper-konjugate
CN114746420A (zh) 2019-06-17 2022-07-12 苏特罗生物制药公司 用于癌症治疗和诊断的作为Toll样受体（TLR）7/8激动剂的1-(4-(氨基甲基)苄基)-2-丁基-2H-吡唑并[3,4-c]喹啉-4-胺衍生物及相关化合物以及其抗体药物偶联物
MX2022011163A (es) 2020-03-11 2022-10-18 Ambrx Inc Conjugados de polipeptidos de interleucina-2 y sus usos.
AU2021327396A1 (en) 2020-08-20 2023-03-23 Ambrx, Inc. Antibody-TLR agonist conjugates, methods and uses thereof
AU2022249223A1 (en) 2021-04-03 2023-10-12 Ambrx, Inc. Anti-her2 antibody-drug conjugates and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4902502A (en) 1989-01-23 1990-02-20 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
US5089261A (en) 1989-01-23 1992-02-18 Cetus Corporation Preparation of a polymer/interleukin-2 conjugate
JPH04218000A (ja) 1990-02-13 1992-08-07 Kirin Amgen Inc 修飾ポリペプチド
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5362852A (en) 1991-09-27 1994-11-08 Pfizer Inc. Modified peptide derivatives conjugated at 2-hydroxyethylamine moieties
NZ244778A (en) 1991-10-21 1994-03-25 Ortho Pharma Corp Peg imidates and protein derivatives thereof
WO1994006151A1 (en) 1992-09-08 1994-03-17 Kabushiki Kaisha Komatsu Seisakusho Method of detecting end point of etching
DE69332524T2 (de) 1992-09-24 2003-04-24 Chiron Corp Synthese von N-substituierten Oligomeren
GB9225448D0 (en) * 1992-12-04 1993-01-27 Erba Carlo Spa Improved synthesis of polymer bioactive conjugates
WO1994028145A2 (en) * 1993-06-01 1994-12-08 Chiron Corporation Expression of urokinase plasminogen activator inhibitors
GB9317618D0 (en) * 1993-08-24 1993-10-06 Royal Free Hosp School Med Polymer modifications
WO1999045026A1 (en) * 1998-03-05 1999-09-10 Chiron Corporation Method for increasing the serum half-life of a biologically active molecule

Also Published As

Publication number Publication date
DE69921102T2 (de) 2006-02-02
WO1999045026A1 (en) 1999-09-10
US20070135349A1 (en) 2007-06-14
US20050197297A1 (en) 2005-09-08
US6423685B1 (en) 2002-07-23
DE69921102D1 (de) 2004-11-18
US20020182705A1 (en) 2002-12-05
US20070060513A9 (en) 2007-03-15
US20020086819A1 (en) 2002-07-04
EP1062230A1 (de) 2000-12-27
JP2002505338A (ja) 2002-02-19
EP1062230B1 (de) 2004-10-13
US7022673B2 (en) 2006-04-04

Similar Documents

Publication Publication Date Title
ATE279430T1 (de) Verfahren zur verbesserung der serum halbwertszeit von biologisch aktiven molekülen
Fulcher et al. Proteolytic inactivation of human factor VIII procoagulant protein by activated human protein C and its analogy with factor V
ATE107960T1 (de) Varianten von menschlichem gewebeplasminogenaktivator sowie verfahren zu deren herstellung.
Matsuda et al. A simple, large scale method for preparation of plasminogen-free fibrinogen
DE69816297T2 (de) Verfahren und zusammensetzungen des gewebefaktors zur koagulation und behandlung von tumoren
ATE249422T1 (de) Verbindungen und zusammensetzungen zur verabreichung aktiver stoffe
DE69719359D1 (de) Cyklische peptide, die an den urokinase-type plasminogen aktivator rezeptor binden
YU21399A (sh) Konjugati koji sadrže delove rastvorljive u vodi, njihova upotreba u proizvodnji leka korisnog za tretiranje raka prostate i farmaceutske kompozicije koje ih sadrže
ATE70301T1 (de) Gewebeplasminogen-aktivator-mutant, dafuer kodierende rekombinante genetische information und verfahren zur herstellung dieser mutanten, deren verwendung und pharmazeutische zusammensetzungen.
DK431988D0 (da) Protein og dna til kodning deraf
ATE104863T1 (de) Pharmazeutische formulierung von plasminogenaktivatorproteinen.
Sumi et al. Higher fibrin-binding and thrombolytic properties of single polypeptide chain-high molecular weight urokinase
Lijnen et al. Mechanisms of plasminogen activation by mammalian plasminogen activators
Maksimenko et al. Water-soluble urokinase derivatives with increased affinity to the fibrin clot
Camacho et al. Limited proteolysis of tumor cells increases their plasmin-binding ability
Furlan et al. Clottability and cross-linking reactivity of fibrin (ogen) following differential release of fibrinopeptides A and B
KR900702017A (ko) 혼성 단백질(bybrid proteins)
DE3780357D1 (de) Plasminogen-aktivator und thrombolytische zusammensetzung.
DE69113049T2 (de) Varianten des gewebeplasminogenaktivators mit vermindertem abbau.
NO951219L (no) Farmasöytisk preparat til behandling av blodklumper og fremgangsmåte til fremstilling derav
ATE483816T1 (de) Systemisches virus/ligand genabgabemittel und gentherapie
Markland Jr et al. The Application of a Snake Venom Anticoagulant Enzyme in Burn Therapy.
Hall Assembly of fibrinolysis proteinases on cell surfaces: Plasminogen-cell surface interactions

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties